Insulet’s Omnipod 5 automated insulin delivery system, first cleared by the FDA in January 2022 for individuals aged six and older with type 1 diabetes, continues to expand its reach and capabilities. As the world’s first tubeless, wearable automated insulin delivery system, Omnipod 5 has broadened access to a wider population, including children and patients previously unable to use automated delivery. Last year, the system became the first and only automated insulin delivery device cleared for both type 1 and type 2 diabetes, supported by positive SECURE-T2D trial data.
At the 2025 American Diabetes Association Scientific Sessions, Insulet’s SVP and Chief Medical Officer Dr. Trang Ly highlighted the company’s strong adoption growth, attributing success to the product’s simplicity and ease of use. Insulet also recently launched a creative partnership with Marvel, featuring a comic book hero with diabetes to raise awareness. Looking ahead, the company is actively pursuing next-generation automation technologies to further expand its insulin patch pump offerings.
Follow MEDWIRE.AI for diabetes tech and automated insulin delivery updates.
